TrialSignal
Clinical trial intelligence report
The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02043886-Jul 28, 2026
NCT ID
NCT02043886
Status
COMPLETED
Phase
PHASE2
Sponsor
University of British Columbia
Executive brief
Investment-Ready Snapshot
The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes is a PHASE2 clinical asset sponsored by University of British Columbia in Type 2 Diabetes, Postprandial Hypotension. SEO and diligence focus: Acarbose, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02043886
Indication
Type 2 Diabetes
Modality
small molecule
Target
Acarbose, Placebo
Intervention
Acarbose, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.